Article Text

other Versions

PDF
Update on systemic vasculitides
  1. Siddiq Anwar1,
  2. M Yousuf Karim2
  1. 1Department of Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
  2. 2Immunology Department, Frimley Park Hospital, Frimley, UK
  1. Correspondence to Dr M Yousuf Karim, Department of Immunology, Frimley Park Hospital, Portsmouth Road, Frimley, Surrey GU16 7UJ, UK; yousuf.karim{at}nhs.net

Abstract

Management of systemic vasculitis has been revolutionised over the last decade with the introduction of targeted biological agents. With an increase in both the prevalence and the recognition of vasculitis as well as the high cost of these agents, it is important to ensure their most optimal utilisation. The goals of vasculitis therapy include the induction and maintenance of remissions, preventing relapses, reducing the toxicity of therapy with the aim of reducing morbidity and mortality as well as improving the quality of life of those afflicted. This review focuses on the recent advances in the diagnosis, surveillance and treatment of these conditions.

  • VASCULITIS
  • ANTIBODIES
  • AUTOANTIBODY
  • IMMUNOLOGY
  • LYMPHOCYTES

Statistics from Altmetric.com

Footnotes

  • Handling editor Stephen Jolles

  • Contributors Both authors contributed to the manuscript.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.